{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:05:17Z","timestamp":1788537917725,"version":"build-2803163510"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ajoc.2022.101489","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T13:46:15Z","timestamp":1647438375000},"page":"101489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Atezolizumab induced immune-related adverse event mimicking conjunctival metastatic disease"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-8345","authenticated-orcid":false,"given":"Julia","family":"Aschauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3008-8192","authenticated-orcid":false,"given":"Ruth","family":"Donner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6218-5317","authenticated-orcid":false,"given":"Jan","family":"Lammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Schmidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ajoc.2022.101489_bib1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/CAD.0000000000000921","article-title":"Immune checkpoint inhibitors for the management of advanced non-small-cell lung carcinoma: a meta-analysis","volume":"31","author":"Lai","year":"2020","journal-title":"Anti Cancer Drugs"},{"issue":"1","key":"10.1016\/j.ajoc.2022.101489_bib2","first-page":"38","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Expert. Rev. Anticancer. Ther. Apr."},{"issue":"6","key":"10.1016\/j.ajoc.2022.101489_bib3","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.ajoc.2022.101489_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Abdel-Rahman","year":"2017","journal-title":"Expert Rev Anticancer Ther. Apr"},{"key":"10.1016\/j.ajoc.2022.101489_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jtos.2021.02.004","article-title":"Ocular surface disease associated with immune checkpoint inhibitor therapy","volume":"20","author":"Park","year":"2021","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.ajoc.2022.101489_bib6","doi-asserted-by":"crossref","first-page":"701951","DOI":"10.3389\/fimmu.2021.701951","article-title":"Ocular immune-related adverse events associated with immune checkpoint inhibitors in lung cancer","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ajoc.2022.101489_bib7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/WNO.0000000000001148","article-title":"Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1\/PD-L1 checkpoint blockade","volume":"41","author":"Sun","year":"2021","journal-title":"J Neuro Ophthalmol"},{"issue":"202","key":"10.1016\/j.ajoc.2022.101489_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajo.2019.02.012","article-title":"Prevalence and clinical patterns of ocular complications associated with anti-PD-1\/PD-L1 anticancer immunotherapy","volume":"6","author":"Bitton","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajoc.2022.101489_bib9","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1136\/bjophthalmol-2020-316970","article-title":"Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience","volume":"105","author":"Fortes","year":"2021","journal-title":"Br. J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.ajoc.2022.101489_bib10","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.ajoc.2022.101489_bib11","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1007\/s00262-020-02635-3","article-title":"Factors associated with ocular adverse event after immune checkpoint inhibitor treatment","volume":"69","author":"Kim","year":"2020","journal-title":"Cancer Immunol Immunother"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993622002353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993622002353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:00:48Z","timestamp":1762527648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993622002353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":11,"alternative-id":["S2451993622002353"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101489","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atezolizumab induced immune-related adverse event mimicking conjunctival metastatic disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101489"}}